Insider Selling: Robert J. Flanagan Sells 16,000 Shares of Sagent Pharmaceuticals Stock (SGNT)
Sagent Pharmaceuticals (NASDAQ:SGNT) Director Robert J. Flanagan unloaded 16,000 shares of the company’s stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $26.51, for a total value of $424,160.00. Following the transaction, the director now directly owns 6,996 shares in the company, valued at approximately $185,464. The sale was disclosed in a filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on SGNT shares. Analysts at Jefferies Group reiterated a “hold” rating on shares of Sagent Pharmaceuticals in a research note on Thursday, May 15th. They now have a $23.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “hold” rating on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $24.00 price target on the stock, up previously from $22.00. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $23.62.
Shares of Sagent Pharmaceuticals (NASDAQ:SGNT) traded down 2.30% during mid-day trading on Wednesday, hitting $26.35. 215,784 shares of the company’s stock traded hands. Sagent Pharmaceuticals has a 1-year low of $17.49 and a 1-year high of $27.57. The stock has a 50-day moving average of $23.26 and a 200-day moving average of $22.33. The company has a market cap of $839.6 million and a P/E ratio of 33.21.
Sagent Pharmaceuticals (NASDAQ:SGNT) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.16 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.02) by $0.18. The company had revenue of $70.90 million for the quarter, compared to the consensus estimate of $65.66 million. The company’s quarterly revenue was up 17.8% on a year-over-year basis. Analysts expect that Sagent Pharmaceuticals will post $0.14 EPS for the current fiscal year.
Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.